A novel tetrahydroquinoline inhibitor of NLRP3, compound 6, specifically inhibits NLRP3 activation in vivo and attenuates colitis severity in the DSS mouse model [167] by directly binding to the NACHT domain of NLRP3, inhibiting its ATPase activity and blocking ASC oligomerization [167]. Here, NLRP3 is linked to colitis.